AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04338737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: timming of feeding
Description: post-operative oral feeding receiving water and clear fluid after surgery, followed by soft food and regular diet
Study NCT01446744 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: palliative radiotherapy
Description: Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:~Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions~Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions~Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions~Liver: 20 Gy in 5 fractions if standard institutional practice
Study NCT04277039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic treatment + cognitive training
Description: This intervention is a combination of manipulative osteopathic treatment and cognitive training to be administered each week for a 12-week study period
Study NCT04277039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: osteopathic treatment
Description: manual treatment using osteopathic procedure. 8 sessions for a 12 week study period
Study NCT04277039 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: administration of non-steroid inflammatory drug according to international guidelines
Study NCT03897595 — intervention group
Intervention type: DEVICE
Intervention: MPact Cup
Description: Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
Study NCT03009968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-void residual free voiding trial
Description: Will proceed with voiding trial and assess bladder emptying based on voided amount without checking a post-void residual.
Study NCT02215005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT02215005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02215005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Study NCT02215005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Study NCT01108198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate cream
Description: Study cream was applicated once per day for 4-8 weeks.
Study NCT01108198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate cream
Description: Study cream was applicated once per day for 4-8 weeks.
Study NCT01108198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moisturizing cream
Description: study cream was applicated once per day for 4 to 8 weeks
Study NCT01108198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moisturizing cream
Description: study cream was applicated once per day for 4 to 8 weeks
Study NCT02242383 — intervention group
Intervention type: DRUG
Intervention: Telmisartan
Study NCT02242383 — intervention group
Intervention type: DRUG
Intervention: Telmisartan in combination with hydrochlorothiazide
Study NCT02259894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX
Study NCT02259894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00730548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device triggered remote telephone contact because of Care Alert
Description: Care Alerts on, physician will be notified in case of an Care Alert. Depending on the outcome of the telephone contact drug adjustment and / or further interventions can be prescribed
Study NCT04071418 — intervention group
Intervention type: RADIATION
Intervention: 3D-printing Template-assisted CT-guided I-125 Seeds Implantation
Description: (1) positioning and preoperative plan design;(2) 3D printing template design and production;(3) reset and seeds implantation;(4) intraoperative optimization;Postoperative dose verification.Dosimetric parameters include: dose D90 and D100 reaching a certain percentage target volume; Target volume V100, V150 and V200 reaching a certain percentage of prescribed dose;And the dose of organs at risk: Dmean, D2cc, d0.5cc, d0.1cc. Regular follow-up was conducted after treatment.
Study NCT04933461 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Safety lancet
Description: There are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
Study NCT01163214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular Injection
Description: Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
Study NCT00857077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Study NCT00857077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04470089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myramistin
Description: Oromucosal application
Study NCT04046731 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin Testing
Description: Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
Study NCT02762331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Comparing safety and efficacy of IV Vitamin C in CABG patients
Study NCT04524013 — intervention group
Intervention type: OTHER
Intervention: There is no intervention. It is an observational study.
Description: There is not intervention
Study NCT02762331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention
Study NCT02055300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005
Study NCT02055300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02055300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02055300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal
Study NCT02055300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pristiq
Study NCT04518488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Personalized and individualized exercises for lower limb soft-tissue sarcoma of each participant in this group.
Study NCT04518488 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Informational Support Group (Control group)
Description: The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period.
Study NCT04591847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 2
Description: Vitamin D2 20000IU 1 tab oral weekly
Study NCT04591847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo drug
Description: Placebo drugs 1 tab oral weekly
Study NCT03212456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid-free group
Description: We'll study if the opioid-free anesthesia can reduce the biochemical recurrence of prostate cancer.
Study NCT03212456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Group
Description: This group will receive fentanyl in the induction of anesthesia.
Study NCT03212456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transversus abdominal plane block with ropivacaine
Description: The opioid-free group will receive transversus abdominal plane block with ropivacaine 0,375% 20 ml each side
Study NCT03212456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominal plane block with placebo
Description: the non-opioid free group will receive transversus abdominal plane block with physiological solution 0,9% 20 ml each side
Study NCT01431963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamictal
Description: No comparison.
Study NCT02790424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging devices
Description: technological adjustment tests
Study NCT03326622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.
Study NCT03326622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.
Study NCT03326622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate exercise
Description: A moderate exercise protocol two times per week in a treadmill in the lower range of the training zone determined by Cardiopulmonary Exercise Testing, monitored by continuous pulse oximetry evaluation.
Study NCT00376896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW876008 200mcg
Description: GW876008
Study NCT00376896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW876008 20mcg
Description: GW876008 20mcg
Study NCT00376896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00951912 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10g soy protein isolated per day
Study NCT00951912 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daidzein
Description: 50mg daidzein +10g soy protein isolated per day
Study NCT00951912 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Genistein
Description: 50mg genistein +10g soy protein isolated per day
Study NCT04717856 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: screening: HCV RNA test and risk factors questionaire
Description: Screening by using a rapid finger prick test for HCV RNA and a questionnaire to assess risk factors.
Study NCT02250586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-CSO
Description: Internet-delivered cognitive-behavioral therapy for CSO's of treatment refusing problem gamblers
Study NCT03099811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive plan
Description: The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval. Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.
Study NCT03099811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
Study NCT03099811 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking cessation
Description: Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
Study NCT03988465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study NCT03949894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: 30mg and 15mg of Tolvaptan Tablet
Study NCT01156246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/Metformin
Description: oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
Study NCT03822689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube F2220
Description: M: Folding D: 22mm; L: 2.0M
Study NCT03822689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube F2216
Description: M: Folding; D: 22mm; L:1.6M
Study NCT03822689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube F1520
Description: M: Folding; D: 15mm; L:2.0M
Study NCT03822689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube F1516
Description: M: Folding; D: 15mm; L:1.6M
Study NCT03822689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube U1016
Description: M: Unfolding; D: 10mm; L:1.6M
Study NCT03822689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube U1516
Description: M: Unfolding; D: 15mm; L:1.6M
Study NCT03822689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube CA20
Description: M: Co-axis; L:2.0M
Study NCT04470089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Myramistin
Description: Oromucosal application
Study NCT04293718 — intervention group
Intervention type: OTHER
Intervention: papillary gum biopsies
Description: 1 or 2 papillary gum biopsies were performed simultaneously, 1 for histological examination and 1 for immunohistochemistry
Study NCT03471442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block
Description: Ultrasound-guided paravertebral block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
Study NCT03471442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Ultrasound-guided erector spinae plane block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
Study NCT03822689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator breathing tube CA16
Description: M: Co-axis; L:1.6M
Study NCT01700855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Electrodes are applied to bilateral Hegu(L14) acupoints at the time of 1h before operation, and connected to Hwato Electronic Acupuncture Treatment Instrument (Model No. SDZ-V, Suzhou Medical Appliances Co., Ltd., Suzhou, China). The acupoints are stimulated at an intensity of 3\~6 mA and a frequency of 2/30 Hz for 30 min. The highest intensity will be chosen at which the patient can tolerate.
Study NCT04833621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES GROUP
Description: The effects of NMES and muscle strengthening and standard physiotherapy exercises on the development of ICU-AW were observed
Study NCT03900000 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy
Description: Ambulatory leg-muscle oriented physiotherapy (2 x 45 minutes per week for at least 8 weeks) at Aachen University Hospital. Daily protocol of leg muscle training, exercises, sufficient fluid intake of 2liter/day, pressure stockings.
Study NCT03040466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: reusable fiberoptic ureteroscope
Description: We will use reusable fiberoptic ureteroscopes for the treatment of kidney and ureter stones.
Study NCT04484610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain
Description: Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.
Study NCT03040466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable digital ureteroscope
Description: We will use disposable digital ureteroscopes for the treatment of kidney and ureter stones.
Study NCT04278547 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISPOT IFN-γ assay
Description: ELISPOT IFN-γ diagnostic test: Evaluation of specific cellular immune response against the IE-1 antigen and the CMV pp65, using the technique ELISPOT IFN-γ and individualize the preventive strategy according to the result. In patients with a ELISPOT of low risk will be made advance therapy (preemptive therapy) guided by PCR of CMV In patients with a high risk ELISPOT, universal prophylaxis with valganciclovir will be performed oral (900 mg / 24h) or intravenous ganciclovir (5-10 mg / Kd / day) in case the oral route is not available.
Study NCT00203294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine, bupivicaine and saline
Description: lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
Study NCT00203294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine plus bupivicaine plus triamcinolone (steroid)
Description: lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
Study NCT00485615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 Joy enteric coated concentrated fish oil
Description: 1500-3000mg; one per day
Study NCT03687229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR)
Description: measure level of serum micro ribonucleic acid -122 and insulin resistance in chronic hepatitis C patients using real time polymerase chain reaction
Study NCT03687229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A)fasting serum glucose, B)Fasting serum insulin
Description: measure level of insulin resistance
Study NCT00566475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
Study NCT02205229 — intervention group
Intervention type: DRUG
Intervention: Multi-ingredient, topical compounded medications
Study NCT05246735 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MR-guided Near Infrared optical tomography
Study NCT00270816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-ß-1b
Description: 250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
Study NCT00270816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon ß-1b
Description: 250 micrograms (8 MIU) administered subcutaneously (sc) every other day
Study NCT04390334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.
Study NCT04390334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Famotidine will be administered orally as 1 film-coated tablet of 40 mg strength to be taken in the morning under fasted conditions.
Study NCT04390334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.
Study NCT03949816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical consultation: different doctor-patient-centered style of communication
Description: Different doctor-patient communication
Study NCT03949816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: information letter / no medical consultation
Description: In the control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
Study NCT03026556 — intervention group
Intervention type: DRUG
Intervention: Dabigatran vs. Rivaroxaban
Description: observed for 6 years
Study NCT03026556 — intervention group
Intervention type: DRUG
Intervention: Dabigatran vs. Apixaban
Description: Observed for 6 years
Study NCT02907866 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound with EBUS scope and with linear ultrasound probe
Description: All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.